Olema Pharmaceuticals (NASDAQ:OLMA) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Olema Pharmaceuticals (NASDAQ:OLMA) from a sell rating to a strong sell rating in a research report report published on Saturday morning.

Other equities analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Guggenheim dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Wolfe Research initiated coverage on shares of Olema Pharmaceuticals in a research note on Friday, March 27th. They issued a “peer perform” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Friday, July 17th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.10.

Olema Pharmaceuticals Stock Up 2.6%

Olema Pharmaceuticals stock opened at $12.01 on Friday. Olema Pharmaceuticals has a 12 month low of $4.47 and a 12 month high of $36.26. The stock has a fifty day simple moving average of $11.59 and a two-hundred day simple moving average of $16.90. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -5.95 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). Equities analysts predict that Olema Pharmaceuticals will post -2.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Siren L.L.C. bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at approximately $82,518,000. Janus Henderson Group PLC raised its stake in Olema Pharmaceuticals by 87.1% during the 4th quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock worth $167,901,000 after acquiring an additional 3,124,345 shares during the period. Cormorant Asset Management LP bought a new stake in Olema Pharmaceuticals during the 4th quarter worth approximately $68,750,000. RA Capital Management L.P. purchased a new position in Olema Pharmaceuticals during the fourth quarter valued at approximately $65,000,000. Finally, Bain Capital Life Sciences Investors LLC lifted its holdings in Olema Pharmaceuticals by 24.3% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after purchasing an additional 1,664,687 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.